Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

1	NAMES OF REPORTING PERSONS
	KKR Group Partnership L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			(a)	☐
				(b)	☐
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)
	OO
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)				☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION
	Cayman Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER
			25,260,971
		8	SHARED VOTING POWER
			0
		9	SOLE DISPOSITIVE POWER
			25,260,971
		10	SHARED DISPOSITIVE POWER
			0
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	25,260,971
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	13.4%
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	PN

Item 2.

Identity and Background.

(i)

KKR Genetic Disorder L.P., a Delaware limited partnership (“KKR Genetic Disorder”);

(ii)

KKR Genetic Disorder GP LLC, a Delaware limited liability company (“KKR Genetic Disorder GP”);

(iii)

KKR Group Partnership L.P., a Cayman Islands exempted limited partnership (“KKR Group Partnership”);

(iv)

KKR Group Holdings Corp., a Delaware corporation (“KKR Group Holdings”);

(v)

KKR Group Co. Inc., a Delaware corporation (“KKR Group Co.”);

(vi)

KKR & Co. Inc., a Delaware corporation (“KKR & Co.”);

(vii)

KKR Management LLP, a Delaware limited liability partnership (“KKR Management”);

(viii)

Henry R. Kravis, a United States citizen; and

(ix)

George R. Roberts, a United States citizen (the persons and entities listed in items (i) through (ix) are collectively referred to herein as the “Reporting Persons”).

Item 4.

Purpose of Transaction.

Item 5.

Interest in Securities of the Issuer.

Item 7.

Materials to be Filed as Exhibits

Exhibit Number		Description
Exhibit I		Joint Filing Agreement, dated as of September 17, 2024, by and among the Reporting Persons.